NOVEXEL BEGINS PHASE I TRIAL FOR NXL 103

Novexel has initiated a multidose Phase I trial of NXL 103, an orally administered antibiotic for the treatment of bacterial respiratory infections.

NXL 103 is a streptogramin-type antibiotic that inhibits proteosynthesis at the level of bacteria. In preclinical studies, it demonstrated powerful activity against all the major pathogens affecting respiratory paths, including strains that are resistant to penicillin, macrolides and quinolone.